Enhanced glucocorticoid sensitivity in patients with chronic fatigue syndrome

Gaab, Jens; Rohleder, Nicolas; Heitz, Vera; Schad, Tanja; Engert, Veronika; Schürmeyer, Thomas H.; Ehlert, Ulrike

doi:10.1034/j.1601-5215.2003.00033.x

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Enhanced glucocorticoid sensitivity in patients with chronic fatigue syndrome

MPS-Authors

There are no MPG-Authors in the publication available

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Gaab, J., Rohleder, N., Heitz, V., Schad, T., Engert, V., Schürmeyer, T. H., et al. (2003). Enhanced glucocorticoid sensitivity in patients with chronic fatigue syndrome. Acta Neuropsychiatrica, 15(4), 184-191. doi:10.1034/j.1601-5215.2003.00033.x.

Cite as: https://hdl.handle.net/21.11116/0000-0005-B1AC-1

Abstract

Objective: Alterations of the immune-neuroendocrine interplay have been described in chronic fatigue syndrome (CFS). Employing a recently developed method, the study set out to investigate whether patients with CFS have an altered sensitivity to glucocorticoids (GCs) when under stress.;

Methods: A total of 21 CFS patients and 20 healthy age- and gender-matched controls underwent a standardized psychosocial stress test (Trier Social Stress Test, TSST). Salivary and plasma cortisol levels were measured repeatedly following exposure to the stressor. GC sensitivity was assessed in vitro by dexamethasone inhibition of lipopolysaccharide-stimulated production of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNC-α).;

Results: Cortisol responses following the TSST did not differ significantly between CFS patients and healthy controls. GC sensitivity differed significantly between CFS patients and healthy controls, with CFS patients showing a greater sensitivity towards GCs (TNF-α: F 1/39 = 7.32, P = 0.01; IL-6: F 1/39 = 9.73, P = 0.004).;

Conclusion: Consistent with recent evidence, CFS patients are characterized by an enhanced sensitivity to glucocorticoids. The implications for secondary processes, such as the regulatory influence of glucocorticoids on immune processes, are discussed.